Overview

Delta sleep-inducing peptide (DSIP) is a nonapeptide first isolated in 1977 from the cerebral venous blood of rabbits electrically stimulated to induce delta-wave sleep. Its endogenous producer and receptor remain incompletely characterised despite five decades of research — DSIP is often described as an “orphan peptide” whose biological role is inferred from its measurable presence and its exogenous effects rather than from a defined receptor pharmacology.

The published literature spans sleep architecture, HPA-axis modulation, opioid-withdrawal research, and antioxidant/stress-resistance studies, primarily in animal models.

Mechanism (as reported in the literature)

  • Sleep-architecture modulation. Rodent EEG studies report increased delta-wave activity and reduced sleep latency without the REM suppression characteristic of benzodiazepines.
  • HPA-axis dampening. Studies indicate DSIP administration reduces stress-induced cortisol/corticosterone elevations in animal models.
  • Opioid-system interactions. Some studies report reductions in withdrawal severity in opioid-dependence models.
  • Antioxidant activity. Research characterises DSIP as producing measurable increases in tissue antioxidant enzyme activity in rodent oxidative-stress models.

Research findings

  • Sleep-onset human studies. Small human studies from the 1980s reported reduced sleep latency and improvements in subjective sleep quality with intravenous DSIP administration (Schneider-Helmert & Schoenenberger, 1983).
  • Chronic-pain and withdrawal work. Small trials in patients with chronic pain and in opioid-withdrawal populations reported symptomatic improvements but were not replicated in larger, controlled studies.
  • Reversal of stress markers. Rat studies of immobilisation stress report reductions in stress-hormone elevations and behavioural correlates of anxiety.

The clinical evidence base is small and dated; DSIP is best characterised as a research peptide.

Common dosing (from reported research protocols)

Reported doses vary widely across studies. Community research writeups typically describe 100–500 mcg subcutaneously in the evening before sleep. Historical clinical work used higher intravenous doses.

Reconstitution

A 5 mg vial reconstituted with 2 mL of bacteriostatic water yields a 2,500 mcg/mL solution.

  • 100 mcg = 0.04 mL = 4 units on a U-100 syringe
  • 500 mcg = 0.20 mL = 20 units

Storage

Reconstituted DSIP is refrigerated at 2–8 °C and reported as stable for approximately 30 days.

  • Sermorelin — a GHRH analog whose nighttime GH-pulse effect is often discussed in sleep-research contexts.
  • Selank — a distinct neuropeptide with anxiolytic effects.

Common stacks

References

  • Schneider-Helmert, D., Schoenenberger, G. A. (1983). “Effects of DSIP in man. Multifunctional psychophysiological properties besides induction of natural sleep.” Neuropsychobiology, 9(4). PMID 6664557.
  • Kovalzon, V. M., Strekalova, T. V. (2006). “Delta sleep-inducing peptide (DSIP): a still unresolved riddle.” Journal of Neurochemistry, 97(2). PMID 16539653.
  • Graf, M. V., Kastin, A. J. (1986). “Delta-sleep-inducing peptide (DSIP): an update.” Peptides, 7(6). PMID 3547402.